|
|
|
| The Efficacy of Cetirizine Hydrochloride Combined with Ultraviolet Therapy in Treating Uremic Pruritus and Its Impact on IL-31 Levels |
| He Yanyan, Liu Shuzhen, Wang Yongli |
| Department of Nephrology,Anyang People's Hospital,Anyang,Henan 455000 |
|
|
|
|
Abstract Objective Investigating the efficacy of cetirizine hydrochloride combined with ultraviolet therapy in treating uremic pruritus and its impact on IL-31 levels. Methods A total of 100 patients with uremic pruritus treated at our hospital from August were enrolled and randomly divided into two groups(50 cases each)based on admission number parity.The control group received cetirizine hydrochloride monotherapy combined with phototherapy,while the treatment group underwent additional narrowband UVB therapy.The study compared clinical efficacy,laboratory parameters,pruritus severity,sleep quality,and adverse reactions between the two groups. Results The treatment group demonstrated significantly higher overall efficacyvs control,(P<0.05).Post-treatment laboratory results revealed markedly lower levels in the treatment group for serum calcium(Ca),phosphorus(P),5-HT,PTH,β2-MG,CRP,TNF-α,and IL-3 compared to controls(all P<0.05).Significant improvements were observed in pruritus and sleep parameters,with the treatment group showing lower scores than controls in VAS,FIIQand PSQI(all P<0.05).No statistically significant difference in adverse reactions was noted between groups(P>0.05). Conclusion The combination of cetirizine hydrochloride and narrowband UVB phototherapy demonstrates significant clinical benefits for uremic pruritus patients,effectively alleviating symptoms,reducing inflammatory markers,relieving itching,and improving sleep quality with favorable safety,indicating substantial clinical application value.
|
|
Received: 02 February 2026
|
|
|
|
|
|
[1] 施雯,刘玉秋,张留平,等.维持性血液透析患者瘙痒症的流行病学调查[J].肾脏病与透析肾移植杂志,2023,32(03):220-225. [2] 魏梦婷. 不同透析方式患者尿毒症性瘙痒症发病情况的比较及其影响因素分析[D].成都医学院,2022. [3] 贺立山,翁孝刚.内科学第七版[M].第四军医大学出版社,2008. [4] 姚树森,范贞.《赫尔辛基宣言》修订与受试者权益保障[J].中国医院,2014,18(02):51-53. [5] 杨洁. 不同血液透析方式与腹膜透析对尿毒症皮肤瘙痒的疗效[J].现代诊断与治疗,2015,26(19):4498-4499. [6] Seiji Watanabe,Kanji Koyama.Visual Analogue Pain Scale with Convenient Digitizer[J].Anesthesiology,1989,71(3):481-485. [7] 黄伟,路金华,郑晓静,等.中药外洗联合盐酸西替利嗪对行血透治疗尿毒症患者皮肤瘙痒症状及睡眠质量的影响[J].海南医学,2022,33(08):993-996. [8] 刘贤臣,唐茂芹,胡蕾,等.匹兹堡睡眠质量指数的信度和效度研究[J].中华精神科杂志,1996,(02):103-107. [9] 陈晓霞,谢席胜,占志朋.地奈德乳膏联合盐酸西替利嗪治疗尿毒症血液透析皮肤瘙痒患者的临床研究[J].中国临床药理学杂志,2024,40(20):2978-2982. [10] 郭维毅,方超,左阳,等.自拟祛风养血润肤液药浴联合盐酸左西替利嗪对维持性血液透析患者皮肤瘙痒的疗效[J].世界临床药物,2024,45(3):299-337. [11] 段雪萍,谢席胜,庞洁玉,等.维持性血液透析患者尿毒症皮肤瘙痒的相关因素[J].西部医学,2023,35(02):232-237. [12] 王朋飞,朱文元,叶益来.银屑病患者经窄谱中波紫外线治疗后继发雀斑样痣1例[J].临床皮肤科杂志,2023,52(3):163-165. [13] 凌雅红,蔡志杰,孟韧,等.银屑颗粒辅助UVB光疗治疗银屑病的临床疗效[J].现代科学仪器,2023,40(6):127-130. [14] 倪世豪,刘东华,何星灵,等.从炎症免疫角度探究心阳片改善尿毒症心肌病的作用和机制[J].环球中医药,2024,17(7):1267-1273. [15] 漆石平,熊美珍.司维拉姆联合血液灌流疗法对尿毒症皮肤瘙痒患者瘙痒程度评分及钙,磷代谢指标的影响[J].医学临床研究,2024,41(11):1676-1678. [16] Oweis AO,Al-Qarqaz F,Bodoor K,Heis L,Alfaqih MA,Almomani R,Obeidat MA,Alshelleh SA.Elevated inter-leukin 31 serum levels in hemodialysis patients are as-sociated with uremic pruritus[J].Cytokine.2021 Feb,138:155369. [17] 肖达平,孔祥静,徐静琳,等.肾衰宁胶囊对腹膜透析患者血清硫酸吲哚酚和硫酸对甲酚的影响[J].中国中西医结合肾病杂志,2024,25(10):918-920. [18] Zhang X,Wang L,Li J.Effect of the Combination of Hemodialysis and Hemoperfusion on Clearing Interleukin-31:A Prospective,Randomized Crossover Trial in Patients under Maintenance Hemodialysis[J].Iran J Kidney Dis.2025 Feb 25,19(1):1-7. [19] 唐露,韩建德,林乃余.紫外线照射对皮肤固有免疫系统影响的研究[J].皮肤科学通报,2023(6):776-780. [20] 姚尚萍,李斌,刘朝霞,等.基于玄府理论探讨健脾开玄解毒汤联合中药药浴治疗斑块状银屑病临床观察[J].辽宁中医药大学学报,2023,25(5):151-155. [21] 王彦江,王海琳,袁心柱,等.尿毒症合并继发性甲状旁腺功能亢进患者甲状旁腺全切术术后HD,CRRT治疗效果对比观察[J].山东医药,2023,63(24):25-29. [22] 赵园园,周乐,徐炳超,等.帕立骨化醇联合连续性肾脏替代治疗对尿毒症合并继发性甲状旁腺功能亢进症患者肾功能和炎症因子水平的影响[J].实用药物与临床,2023,26(12):1089-1093. [23] 寇尧. 脊髓背角ERα+神经元促进痒觉信息传递的机制研究[D].延安大学,2022. |
| [1] |
Zheng Yongjian, Zhuang Feicui, Huang Zhaoxin, Xiao Huiliang. Clinical Effect Evaluation of Prone Position Mechanical Ventilation in the Treatment of Severe Aspiration Pneumonia Complicated with Acute Respiratory Distress Syndrome[J]. journal1, 2026, 46(1): 12-14. |
| [2] |
. [J]. journal1, 2026, 46(1): 108-110. |
| [3] |
. [J]. journal1, 2025, 45(6): 72-74. |
| [4] |
. [J]. journal1, 2025, 45(6): 78-80. |
| [5] |
. [J]. journal1, 2025, 45(6): 69-71. |
| [6] |
. [J]. journal1, 2025, 45(6): 137-139. |
|
|
|
|